I'm LongbridgeAI, I can summarize articles.Autonomix Medical has been granted U.S. Patent No. 12,611,134 for a catheter-based platform diagnosing and treating overactive bladder by mapping electrophysiological signals and delivering targeted therapy. The patent also covers an implantable device concept for long-term monitoring and potential drug delivery. The company holds a global portfolio of 112 issued or pending patents expiring in the late 2030s, targeting the 37 million Americans affected by the condition.
- Autonomix Medical received U.S. Patent No. 12,611,134 for devices, systems and methods to diagnose and treat overactive bladder. * Patent covers a catheter-based platform that maps bladder-wall electrophysiological signals, then delivers targeted therapy with post-treatment verification. * Also includes an implantable bladder device concept for long-term monitoring, with potential localized drug delivery. * Company cited an intellectual property portfolio of 112 issued or pending patent applications worldwide, with expirations extending into the late 2030s. * Targets the urology market for overactive bladder, which it estimates affects about 37 million Americans. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autonomix Medical Inc. published the original content used to generate this news brief on July 15, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here